TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.

TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.

Hypoxia and interactions with bone marrow (BM) stromal cells have emerged as essential components of the leukemic BM microenvironment in promoting leukemia cell survival and chemoresistance. High levels of transforming growth factor beta 1 (TGFβ1) produced by BM stromal cells in the BM niche regulat...

Full description

Bibliographic Details
Main Authors:	Yoko Tabe, Yue Xi Shi, Zhihong Zeng, Linhua Jin, Masato Shikami, Yasuhito Hatanaka, Takashi Miida, Frank J Hsu, Michael Andreeff, Marina Konopleva
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3695026?pdf=render

Similar Items

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
by: Yoko Tabe, et al.
Published: (2020-02-01)

Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway.
by: Bin Yuan, et al.
Published: (2020-01-01)

Effects of Combinatory In Vitro Treatment with Immune Checkpoint Inhibitors and Cytarabine on the Anti-Cancer Immune Microenvironment in De Novo AML Patients
by: Łukasz Bołkun, et al.
Published: (2024-01-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: Shahriari Ahmadi A, et al.
Published: (2004-08-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: A Shahriari Ahmadi, et al.
Published: (2004-03-01)

The role of AML secretome and bone marrow microenvironment in establishment and maintenance of leukaemia initiating cells
by: Ren, X
Published: (2023)

Far from Health: The Bone Marrow Microenvironment in AML, A Leukemia Supportive Shelter
by: Stephanie Sendker, et al.
Published: (2021-05-01)

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
by: Kotoko Yamatani, et al.
Published: (2022-04-01)

P443: IMPACT OF PHARMACOGENETIC VARIANTS ON CYTARABINE AND ANTHRACYCLINE EFFECT ON OUTCOMES IN ADULT AML PATIENTS
by: Z. Pravdic, et al.
Published: (2022-06-01)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
by: Xiao-Hua Luo, et al.
Published: (2023-08-01)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
by: Emmanuel Gyan, et al.
Published: (2022-06-01)

CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-β Signaling
by: Bo-Reum Kim, et al.
Published: (2020-06-01)

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
by: Anthony P. Schwarer, et al.
Published: (2018-12-01)

PB1838: TOXICITY AND OUTCOME OF HIGH DOSE CYTARABINE (18 G/M2) FOR AML CONSOLIDATION.
by: L. Lopes, et al.
Published: (2022-06-01)

S128: AML CONDITIONING OF THE BONE MARROW MICROENVIRONMENT THROUGH CCR1 LIGAND UP-REGULATION PROMOTES AML STEM CELL PROPAGATION AND IS MIMICKED BY AGEING
by: Xiying Ren, et al.
Published: (2023-08-01)

Effect of Granulocyte Colony-Stimulating Factor on the Development of Spermatogenesis in the Adulthood of Juvenile AML Mice Model Treated with Cytarabine
by: Bara’ah Khaleel, et al.
Published: (2023-07-01)

Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis
by: Barbara Tomic, et al.
Published: (2022-07-01)

Disrupting the LC3 Interaction Region (LIR) Binding of Selective Autophagy Receptors Sensitizes AML Cell Lines to Cytarabine
by: Mateusz Putyrski, et al.
Published: (2020-03-01)

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
by: Katie Fooks, et al.
Published: (2022-12-01)

Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
by: Chengzhi Xie, et al.
Published: (2013-01-01)

Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
by: Jill Nehrbas, et al.
Published: (2020-02-01)

Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein
by: Jiang Cao, et al.
Published: (2016-11-01)

Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML
by: Marcus Bauer, et al.
Published: (2024-12-01)

Cytarabine-Induced Encephalitis
by: Christine Lenfant, et al.
Published: (2021-09-01)

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
by: Jun Li, et al.
Published: (2022-12-01)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
by: Jingyi Zhang, et al.
Published: (2022-04-01)

High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification
by: Xiaoyu Wang, et al.
Published: (2023-01-01)

Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis.
by: Patricia Macanas-Pirard, et al.
Published: (2012-01-01)

Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma.
by: Shannon Kidd, et al.
Published: (2012-01-01)

Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
by: Tomislav Smoljo, et al.
Published: (2023-10-01)

Bone Marrow Microenvironment-Induced Chemoprotection in <i>KMT2A</i> Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination
by: Kara M. Lehner, et al.
Published: (2023-06-01)

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways
by: Maryam Bakhtiyari, et al.
Published: (2023-09-01)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
by: L. Minarik, et al.
Published: (2022-06-01)

Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study
by: Jing Liu, et al.
Published: (2022-01-01)

In vitro Evaluation of Cytarabin Induced Apoptosis in Leukemic Blasts
by: Tahereh Zieh, et al.
Published: (2005-12-01)

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML
by: Paola Minetto, et al.
Published: (2023-08-01)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
by: Prajwal Boddu, et al.
Published: (2018-09-01)

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines
by: Jonas B. Lang, et al.
Published: (2022-10-01)

Mechanisms of response and resistance to AML therapies
by: Stoilova, B, et al.
Published: (2020)

2559 Role of tissue non-specific alkaline phosphatase (TNAP) in promoting the survival of acute myeloid leukemia (AML) cells within the bone marrow microenvironment
by: Bradley Bowles, et al.
Published: (2018-06-01)